Biotricity (BTCY) Competitors $0.67 -0.01 (-1.53%) As of 01:52 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainSEC FilingsTrendsBuy This Stock BTCY vs. NTRB, LUNG, QTI, TELA, CTSO, SURG, DXR, PYPD, SRTS, and CTCXShould you be buying Biotricity stock or one of its competitors? The main competitors of Biotricity include Nutriband (NTRB), Pulmonx (LUNG), QT Imaging (QTI), TELA Bio (TELA), Cytosorbents (CTSO), SurgePays (SURG), Daxor (DXR), PolyPid (PYPD), Sensus Healthcare (SRTS), and Carmell (CTCX). These companies are all part of the "medical equipment" industry. Biotricity vs. Its Competitors Nutriband Pulmonx QT Imaging TELA Bio Cytosorbents SurgePays Daxor PolyPid Sensus Healthcare Carmell Biotricity (NASDAQ:BTCY) and Nutriband (NASDAQ:NTRB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability. Which has preferable earnings and valuation, BTCY or NTRB? Nutriband has lower revenue, but higher earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiotricity$12.06M1.39-$14.09M-$0.21-3.20Nutriband$2.58M33.38-$10.48M-$2.87-2.49 Do analysts prefer BTCY or NTRB? Nutriband has a consensus price target of $13.00, suggesting a potential upside of 81.82%. Given Nutriband's stronger consensus rating and higher possible upside, analysts plainly believe Nutriband is more favorable than Biotricity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Nutriband 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of BTCY or NTRB? 3.9% of Biotricity shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 10.1% of Biotricity shares are owned by company insiders. Comparatively, 54.1% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, BTCY or NTRB? Biotricity has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Does the media refer more to BTCY or NTRB? In the previous week, Nutriband had 7 more articles in the media than Biotricity. MarketBeat recorded 8 mentions for Nutriband and 1 mentions for Biotricity. Biotricity's average media sentiment score of 0.32 beat Nutriband's score of -0.14 indicating that Biotricity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biotricity 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nutriband 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Is BTCY or NTRB more profitable? Biotricity has a net margin of -80.42% compared to Nutriband's net margin of -398.29%. Biotricity's return on equity of 0.00% beat Nutriband's return on equity.Company Net Margins Return on Equity Return on Assets Biotricity-80.42% N/A -188.47% Nutriband -398.29%-85.40%-73.45% SummaryNutriband beats Biotricity on 9 of the 16 factors compared between the two stocks. Get Biotricity News Delivered to You Automatically Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTCY vs. The Competition Export to ExcelMetricBiotricitySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.72M$71.14M$5.70B$10.27BDividend YieldN/AN/A5.72%4.60%P/E Ratio-0.6210.7875.8626.51Price / Sales1.3949.76491.12165.50Price / CashN/A18.4125.8129.89Price / Book-0.5210.8412.846.32Net Income-$14.09M-$25.86M$3.28B$270.51M7 Day Performance10.00%-2.83%0.22%2.15%1 Month Performance6.44%-0.04%4.61%6.35%1 Year Performance105.20%60.35%68.33%25.49% Biotricity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTCYBiotricityN/A$0.67-1.5%N/A+75.2%$16.72M$12.06M-0.6240Gap UpNTRBNutriband2.9444 of 5 stars$6.08-2.9%$13.00+113.8%+50.8%$69.82M$2.14M-6.7610Earnings ReportShort Interest ↓LUNGPulmonx3.4234 of 5 stars$1.69-0.6%$7.66+353.5%-80.9%$69.27M$90.55M-1.18250QTIQT ImagingN/A$2.52+1.6%N/A+388.0%$68.38M$4.00M0.00N/ATELATELA Bio2.6831 of 5 stars$1.60-1.2%$4.50+181.3%-40.4%$64.18M$75.32M-1.43120Positive NewsCTSOCytosorbents2.798 of 5 stars$1.00+1.6%$5.50+451.1%-15.3%$61.66M$35.60M-5.87220News CoveragePositive NewsAnalyst ForecastSURGSurgePays3.095 of 5 stars$2.79+1.1%$9.00+222.6%+81.5%$56.39M$60.88M-1.1240Negative NewsDXRDaxor4.077 of 5 stars$11.40-0.1%$25.00+119.3%+28.8%$55.19M$3.31M0.0037News CoverageShort Interest ↓Gap DownPYPDPolyPid3.498 of 5 stars$3.49+0.9%$12.40+255.3%-2.2%$55.00MN/A-0.9180News CoveragePositive NewsShort Interest ↓Gap UpSRTSSensus Healthcare2.7374 of 5 stars$3.27+1.2%$8.00+144.6%-48.3%$53.10M$37.56M-54.5040CTCXCarmellN/A$2.43-4.7%N/A+307.7%$50.80M$32.84K0.0014 Related Companies and Tools Related Companies Nutriband Alternatives Pulmonx Alternatives QT Imaging Alternatives TELA Bio Alternatives Cytosorbents Alternatives SurgePays Alternatives Daxor Alternatives PolyPid Alternatives Sensus Healthcare Alternatives Carmell Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTCY) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotricity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTCY Stock Alerts